CD8+TRM cells have been reported to enhance cancer-killing responses in BC,241,612 melanoma,239,613 NSCLC,197,240 cervical cancer,9 high-grade serous ovarian cancer (HGSC),163 HCC,614 and intrahepatic cholangiocarcinoma.614,615 The levels of CD8+TRM cells have positive clinical prognostic value for these cancer patients. This evidence concerns the gene CD8A and melanoma.